Prinston's Generic Candesartan Cilexetil Receives Approval in the U.S.
Enforcement Report - Week of September 22, 2021
Enforcement Report - Week of April 21, 2021
AstraZeneca has completed the divestment of commercial rights to Atacand (candesartan cilexetil) and Atacand Plus in over 70 countries to German pharmaceutical firm Cheplapharm Arzneimittel.
AstraZeneca has completed the divestment of commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in over 70 countries to Cheplapharm Arzneimittel GmbH (Cheplapharm).
Enforcement Report - Week of January 23, 2019
43 popular heart drugs found to contain carcinogens in Taiwan
FDA is publishing interim acceptable intake levels of nitrosamine impurities in angiotensin II receptor blockers (ARBs) for manufacturers to use to ensure their finished drug products are safe for patients.
Alembic Pharms' Generic Candesartan Cilexetil Receives Approval in US
Valsartan from Mylan laboratories in India can no longer be used in EU medicines due to NDEA impurity